Adverum Biotechnologies Revenue 2013-2021 | ADVM

Adverum Biotechnologies revenue from 2013 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Adverum Biotechnologies Annual Revenue
(Millions of US $)
2020 $
2019 $0
2018 $2
2017 $2
2016 $1
2015 $2
2014 $1
2013 $0
2012 $0
Adverum Biotechnologies Quarterly Revenue
(Millions of US $)
2021-06-30
2021-03-31 $8
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30 $0
2019-06-30
2019-03-31
2018-12-31 $0
2018-09-30 $1
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $1
2015-09-30 $1
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31
2013-09-30 $0
2013-06-30 $0
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.200B $0.000B
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum?s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43